Percentage of Histamine Release After Intradermal Injection of MCP-1 and RANTES
| Treatment . | . | P< . |
|---|---|---|
| PBS (control) | ND | — |
| FMLP 10−6 mol/L | 30 ± 5 | — |
| LPS 10 ng | 42 ± 8 | — |
| MCP-1 10 ng | 20 ± 3 | (*) |
| MCP-1 20 ng | 25 ± 6 | (**) |
| RANTES 10 ng | 34 ± 5 | .05 |
| RANTES 20 ng | 40 ± 7 | .05 |
| Treatment . | . | P< . |
|---|---|---|
| PBS (control) | ND | — |
| FMLP 10−6 mol/L | 30 ± 5 | — |
| LPS 10 ng | 42 ± 8 | — |
| MCP-1 10 ng | 20 ± 3 | (*) |
| MCP-1 20 ng | 25 ± 6 | (**) |
| RANTES 10 ng | 34 ± 5 | .05 |
| RANTES 20 ng | 40 ± 7 | .05 |
Percent release of total histamine by a 50 μL intradermal injection in skin tissue treated with PBS, FMLP, LPS, MCP-1, and RANTES. P values were calculated comparing MCP-1 10 ng (*) with RANTES 10 ng and MCP-1 20 ng (**) with RANTES 20 ng.